Endocrinology in pregnancy: Management of the pregnant patient with a prolactinoma

Mark E Molitch*

*Corresponding author for this work

Research output: Contribution to journalReview article

65 Scopus citations

Abstract

A woman with a prolactinoma is usually infertile. Dopamine agonists usually restore ovulation and fertility and such treatment generally is preferred over transsphenoidal surgery because of higher efficacy and safety. Cabergoline is usually preferred over bromocriptine because of its better efficacy with fewer adverse effects. Either drug increases the rates of spontaneous abortions, preterm deliveries, multiple births, or congenital malformations over what may be expected. However, the number of pregnancies reporting such experience is about sevenfold greater for bromocriptine. Tumor growth causing significant symptoms and requiring intervention has been reported to occur in 2.4% of those with microadenomas, 21% in those with macroadenomas without prior surgery or irradiation, and 4.7% of those with macroadenomas with prior surgery or irradiation. Visual fields should be assessed periodically during gestation in women with macroadenomas. If significant tumor growth occurs, most patients respond well to reinstitution of the dopamine agonist. Delivery of the baby and placenta can also be considered if the pregnancy is sufficiently advanced. Transsphenoidal debulking of the tumor is rarely necessary.

Original languageEnglish (US)
Pages (from-to)R205-R213
JournalEuropean Journal of Endocrinology
Volume172
Issue number5
DOIs
StatePublished - Jan 1 2015

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Endocrinology in pregnancy: Management of the pregnant patient with a prolactinoma'. Together they form a unique fingerprint.

  • Cite this